The antipsychotic lumateperone (Caplyta) and the hypnotic lemborexant (Dayvigo) are the newest in their class. Both of them claim to improve on the safety of older medications, and we look at the data to see how those claims hold up.
Chris Aiken, MD
Talia Puzantian, PharmD, BCPP
Dr. Aiken and Dr. Puzantian have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The FDA rarely issues absolute contraindications, but that’s where their language is tilting in a new warning on Z-Hypnotics. We look at the data behind their decision and offer six tips for safer prescribing of sleep medications.
Nicholas Rosenlicht, MDDr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Recent trials cast doubt on prazosin’s role in PTSD, but there are reasons to doubt their results.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum convallis hendrerit arcu, quis iaculis orci fermentum sed. Mauris nec est non sem eleifend tincidunt nec quis quam. Suspendisse potenti.
Insomnia is one of the most common comorbidities you’ll see in your depressed and anxious patients. But it is often misunderstood. While the common view is that insomnia is caused by a primary psychiatric or medical condition, it is more accurate to simply say that patients have insomnia and depression at the same time. Insomnia is almost never an isolated problem.
Clearly, sleeping pills work; the more relevant issue is whether there are any significant differences among them, and whether we should pony up 3 dollars per pill for the Maserati medications or just 3 cents per pill for perfectly adequate Civics.
You wrote an excellent book on non-pharmacological approaches to insomnia, and I’d like to go over some of the techniques you suggested. What are some practical techniques that psychiatrists can use in the context of short visits with patients?